Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2017 Summary Human Papillomavirus Protein E7 (E7) pipeline Target constitutes close to 38 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2017, outlays comprehensive information on the Human Papillomavirus Protein E7 (E7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Human Papillomavirus Protein E7 (E7) - Human Papilloma Virus (HPV) E7 protein belongs to a group of proteins called oncoproteins. It plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle. E7 protein has both transforming and trans-activating activities. It induces the disassembly of the E2F1 transcription factor from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes. Ii interferes with host histone deacetylation mediated by HDAC1 and HDAC2, leading to transcription activation. It plays an important role in the inhibition of both antiviral and antiproliferative functions of host inteferon alpha. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 3, 13, 1 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Cancer, Anal Cancer, Oropharyngeal Cancer, Hepatocellular Carcinoma, Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Non-Small Cell Lung Carcinoma, Rectal Cancer and Recurrent Head And Neck Cancer Squamous Cell Carcinoma. Furthermore, this report also reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E7 (E7) - The report reviews Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics and enlists all their major and minor projects - The report assesses Human Papillomavirus Protein E7 (E7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Human Papillomavirus Protein E7 (E7) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E7 (E7) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E7 (E7) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Human Papillomavirus Protein E7 (E7) - Overview 9 Human Papillomavirus Protein E7 (E7) - Therapeutics Development 10 Products under Development by Stage of Development 10 Products under Development by Therapy Area 11 Products under Development by Indication 12 Products under Development by Companies 13 Products under Development by Universities/Institutes 19 Human Papillomavirus Protein E7 (E7) - Therapeutics Assessment 21 Assessment by Mechanism of Action 21 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Human Papillomavirus Protein E7 (E7) - Companies Involved in Therapeutics Development 26 Abion Inc 26 Advaxis Inc 26 Bioleaders Corp 27 BioNTech AG 27 Cancer Research Technology Ltd 28 Etubics Corp 28 Formune SL 29 Genexine Inc 29 Hookipa Biotech AG 30 iBio Inc 30 Immunovaccine Inc 31 Inovio Pharmaceuticals Inc 31 MedImmune LLC 32 Selecta Biosciences Inc 32 Transgene SA 33 VLPbio 33 Human Papillomavirus Protein E7 (E7) - Drug Profiles 34 ABN-301 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 axalimogene filolisbac - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 axalimogene filolisbac second generation - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 BLSILSB-710c - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 BVAC-C - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 CerviVax - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 CUE-101 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 CUE-201 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 DNA Vaccine to Target E7 for HPV Associated Cancers - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 DPXE-7 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 EDA-HPVE7 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 ETBX-041 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 GLBL-101c - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 GX-188E - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 HB-201 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 human papillomavirus [Serotype 16] vaccine - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 human papillomavirus [serotypes 16] vaccine - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 human papillomavirus vaccine - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 INO-3106 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 MEDI-0457 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 PVX-01 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 Recombinant Vector Vaccine to Target Human Papillomavirus Protein E7 for HPV Associated Cervical Cancer - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 SEL-701 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 TA-CIN - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 TG-4001 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 Tricurin - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 TTFC-E7SH - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 VGX-3100 - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 Vvax-001 - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 Human Papillomavirus Protein E7 (E7) - Dormant Products 101 Human Papillomavirus Protein E7 (E7) - Discontinued Products 103 Human Papillomavirus Protein E7 (E7) - Product Development Milestones 104 Featured News & Press Releases 104 Jul 13, 2017: Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders 104 Jun 26, 2017: Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 104 Jun 19, 2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer 105 Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer 106 May 18, 2017: Advaxis to Host Investor & Analyst Day on June 12 107 May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer 107 Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers 108 Apr 18, 2017: Immunovaccine Announces Dosing of First Patient in Investigator-Sponsored Phase 1b/2 Clinical Trial Evaluating Immuno-Oncology Candidate Targeting Incurable HPV-Related Cancers 108 Mar 27, 2017: Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac 109 Mar 23, 2017: EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer 110 Mar 22, 2017: Cue Biopharma Announces Selection of Lead Candidate Cue-101 Targeting Human Papillomavirus -Associated Cancers 110 Mar 15, 2017: Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO's Annual Meeting on Women's Cancer 110 Mar 06, 2017: Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech 112 Feb 06, 2017: Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer 112 Jan 30, 2017: GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology's Annual Meeting on Women's Cancer 113 Appendix 115 Methodology 115 Coverage 115 Secondary Research 115 Primary Research 115 Expert Panel Validation 115 Contact Us 115 Disclaimer 116
List of Tables
Number of Products under Development by Stage of Development, H2 2017 10 Number of Products under Development by Therapy Areas, H2 2017 11 Number of Products under Development by Indication, H2 2017 12 Number of Products under Development by Companies, H2 2017 13 Number of Products under Development by Companies, H2 2017 (Contd..1) 14 Products under Development by Companies, H2 2017 15 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18 Number of Products under Investigation by Universities/Institutes, H2 2017 19 Products under Investigation by Universities/Institutes, H2 2017 20 Number of Products by Stage and Mechanism of Actions, H2 2017 21 Number of Products by Stage and Route of Administration, H2 2017 23 Number of Products by Stage and Molecule Type, H2 2017 25 Pipeline by Abion Inc, H2 2017 26 Pipeline by Advaxis Inc, H2 2017 26 Pipeline by Bioleaders Corp, H2 2017 27 Pipeline by BioNTech AG, H2 2017 27 Pipeline by Cancer Research Technology Ltd, H2 2017 28 Pipeline by Etubics Corp, H2 2017 28 Pipeline by Formune SL, H2 2017 29 Pipeline by Genexine Inc, H2 2017 29 Pipeline by Hookipa Biotech AG, H2 2017 30 Pipeline by iBio Inc, H2 2017 30 Pipeline by Immunovaccine Inc, H2 2017 31 Pipeline by Inovio Pharmaceuticals Inc, H2 2017 31 Pipeline by MedImmune LLC, H2 2017 32 Pipeline by Selecta Biosciences Inc, H2 2017 32 Pipeline by Transgene SA, H2 2017 33 Pipeline by VLPbio, H2 2017 33 Dormant Products, H2 2017 101 Dormant Products, H2 2017 (Contd..1), H2 2017 102 Discontinued Products, H2 2017 103
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
